AbbVie (ABBV) wins FDA approval for venetoclax+acalabrutinib, first all‑oral fixed‑duration frontline CLL

AbbVie wins FDA clearance for first all‑oral, fixed‑duration frontline CLL regimen

AbbVie announces that the U.S. Food and Drug Administration approves a supplemental new drug application for the all‑oral combination of VENCLEXTA (venetoclax) and acalabrutinib as a first‑line treatment for previously untreated adults with chronic lymphocytic leukemia (CLL). The approval, supported by data from the AstraZeneca‑sponsored Phase 3 AMPLIFY trial, designates the regimen as the first and only all‑oral, fixed‑duration option in that setting and positions AbbVie to offer a time‑limited targeted strategy intended to give patients treatment-free intervals compared with continuous therapies.

The AMPLIFY trial is a global, multicenter study that compares the venetoclax‑acalabrutinib combination, given for a fixed duration of 14 cycles of 28 days, against investigator‑choice chemoimmunotherapy (fludarabine‑cyclophosphamide‑rituximab or bendamustine‑rituximab) given for six cycles. The approval applies to previously untreated patients without del(17p) or TP53 mutation, reflecting the trial’s enrollment criteria and underpinning the regulatory filing. AbbVie frames the label extension as expanding front‑line choices for clinicians managing a disease that often requires long durations of care.

Company executives and patient advocates signal the approval as a meaningful clinical option. Svetlana Kobina, AbbVie’s vice president of global medical affairs, oncology, emphasizes that oral administration and a fixed‑duration approach may reduce the burden of prolonged treatment and complex ongoing management. Dr. Brian Koffman of the CLL Society highlights the value to patients of an oral, time‑limited front‑line option available in the United States.

Trial backbone and partner role

AMPLIFY is sponsored by AstraZeneca and serves as the primary evidence base for the sNDA; it evaluates the combination either alone or with obinutuzumab against standard chemoimmunotherapy in previously untreated patients without high‑risk TP53 mutations. The trial’s fixed‑duration schema—14 28‑day cycles for the venetoclax‑acalabrutinib arm—reflects a deliberate strategy to test time‑limited targeted therapy versus continuous or shorter chemo regimens.

Implications for CLL care

Clinicians and patient groups view the approval as expanding individualized care options in CLL, offering an alternative to ongoing kinase inhibitor therapy or chemoimmunotherapy for eligible patients. AbbVie presents the milestone as significant for both the company’s oncology portfolio and the broader effort to reduce treatment burden in adult leukemia management.